Novartis copy of Amgen arthritis drug highly similar: FDA staff
Novartis AG’s cheaper version of Amgen Inc’s blockbuster arthritis drug Enbrel is highly similar in potency and safety to the original, according to a review by Food and Drug Administration staff. The review, posted on the FDA’s website on Monday, comes two days ahead of a meeting of outside advisors who will discuss the drug and recommend whether it should be approved. The FDA is not obliged to follow the recommendations of its advisory panels but typically does so.
More From Around the Web
Check out these Articles
- Britain launching global superbug fight
- World’s top drugmaker Novartis takes aim at tech
- Bill Cosby charged with felony sexual assault in Pennsylvania
- Drug industry bemoans Britain’s lack of science skills
- Ex-Valeant executive, ex-pharmacy CEO charged for fraud scheme
- FDA approves Sanofi/Regeneron cholesterol drug with limits
- Older stroke patients may not get needed anti-clotting drugs
- Sierra Leone ‘hero’ doctor’s death exposes slow Ebola res...
- Company says will cut price of drug after accused gouging
- Closely watched AstraZeneca cancer drug fails in mesothelioma
- Could involving patients decrease antibiotic prescriptions?
- DaVita Healthcare Partners to pay $450 million for violating False Claims A...
- 23andMe launches new consumer test service to check for genetic disorders
- Romania’s Antibiotice to boost exports to the U.S.
- Pfizer, Bristol revive cancer drugs that rev up immune system
- WHO consulting ethics experts on experimental Ebola drugs